Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Fate Therapeutics stock

Learn how to easily invest in Fate Therapeutics stock.

Fate Therapeutics Inc is a biotechnology business based in the US. Fate Therapeutics shares (FATE) are listed on the NASDAQ and all prices are listed in US Dollars. Fate Therapeutics employs 542 staff and has a trailing 12-month revenue of around $68.3 million.

How to buy shares in Fate Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FATE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Fate Therapeutics stock price (NASDAQ: FATE)

Use our graph to track the performance of FATE stocks over time.

Fate Therapeutics shares at a glance

Information last updated 2022-09-19.
Latest market close$21.97
52-week range$17.10 - $70.94
50-day moving average $30.14
200-day moving average $34.79
Wall St. target price$74.55
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.44

Buy Fate Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fate Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fate Therapeutics price performance over time

Historical closes compared with the close of $21.97 from 2022-09-23

1 week (2022-09-19) -13.20%
1 month (2022-08-26) -20.20%
3 months (2022-06-24) -18.02%
6 months (2022-03-22) N/A
1 year (2021-09-24) -66.12%
2 years (2020-09-25) -41.88%
3 years (2019-09-26) 40.03%
5 years (2017-09-26) 447.88%

Fate Therapeutics financials

Revenue TTM $68.3 million
Gross profit TTM $55.8 million
Return on assets TTM -19.31%
Return on equity TTM -38.08%
Profit margin 0%
Book value $5.99
Market capitalisation $2.4 billion

TTM: trailing 12 months

Fate Therapeutics share dividends

We're not expecting Fate Therapeutics to pay a dividend over the next 12 months.

Fate Therapeutics share price volatility

Over the last 12 months, Fate Therapeutics's shares have ranged in value from as little as $17.1 up to $70.94. A popular way to gauge a stock's volatility is its "beta".

FATE.US volatility(beta: 1.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fate Therapeutics's is 1.6728. This would suggest that Fate Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Fate Therapeutics overview

Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc.

Frequently asked questions

What percentage of Fate Therapeutics is owned by insiders or institutions?
Currently 1.586% of Fate Therapeutics shares are held by insiders and 117.22% by institutions.
How many people work for Fate Therapeutics?
Latest data suggests 542 work at Fate Therapeutics.
When does the fiscal year end for Fate Therapeutics?
Fate Therapeutics's fiscal year ends in December.
Where is Fate Therapeutics based?
Fate Therapeutics's address is: 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
What is Fate Therapeutics's ISIN number?
Fate Therapeutics's international securities identification number is: US31189P1021
What is Fate Therapeutics's CUSIP number?
Fate Therapeutics's Committee on Uniform Securities Identification Procedures number is: 31189P102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site